22216-44-0

Basic information

• Product Name: (4-METHOXY-3-NITROBENZYL)THIO]ACETIC ACID
• Synonyms: (4-METHOXY-3-NITROBENZYL)THIO]ACETIC ACID;2-[[(4-Methoxy-3-nitrophenyl)methyl]thio]acetic acid;2-(4-Methoxy-3-nitrobenzylthio)acetic acid, 4-Methoxy-3-nitrobenzylthioacetic acid;2-(4-Methoxy-3-nitrobenzylthio)acetic acid;Acetic acid, 2-[[(4-methoxy-3-nitrophenyl)methyl]thio]-
• CAS NO: 22216-44-0
• Molecular Formula: C₁₀H₁₁NO₅S
• Molecular Weight: 257.26
• Mol File: 22216-44-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 470.2 °C at 760 mmHg
• Flash Point: 238.2 °C
• Appearance: /
• Density: 1.404
• Refractive Index: 1.606
• CAS DataBase Reference: (4-METHOXY-3-NITROBENZYL)THIO]ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (4-METHOXY-3-NITROBENZYL)THIO]ACETIC ACID(22216-44-0)
• EPA Substance Registry System: (4-METHOXY-3-NITROBENZYL)THIO]ACETIC ACID(22216-44-0)

Safety Data

• Hazardous Substances Data: 22216-44-0(Hazardous Substances Data)

Usage

General Description

(4-Methoxy-3-nitrobenzyl)thio]acetic acid is a chemical compound with the molecular formula C9H9NO5S. It is a derivative of benzylthioacetic acid and contains both a methoxy and nitro group on the benzene ring. (4-METHOXY-3-NITROBENZYL)THIO]ACETIC ACID has been studied for its potential pharmaceutical applications, particularly in the development of new drugs. It may also have uses in organic synthesis and chemical research. The precise properties and uses of this compound are still being explored, making it an area of interest for further investigation and study in the field of chemistry.

InChI:InChI=1/C10H11NO5S/c1-16-9-3-2-7(4-8(9)11(14)15)5-17-6-10(12)13/h2-4H,5-6H2,1H3,(H,12,13)

Upstream product

• 6378-19-4 4-methoxy-3-nitrobenzyl chloride 
• 3011-34-5 4-hydroxy-3-nitrobenzaldehyde 
• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 
• 41870-24-0 (4-methoxy-3-nitrophenyl)methanol 
• 119-10-8 4-methoxy-3-nitrotoluene 
• 61010-34-2 3-nitro-4-methoxybenzyl bromide 
• 68-11-1 mercaptoacetic acid 
• 367-51-1 sodium 2-mercaptoacetate 

Downstream Products

• 592542-59-1 (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic acid 
• 852283-21-7 (E)-2-methoxy-5-((2,4,6-trimethoxystyrylsulfinyl)methyl)aniline 
• 1310065-00-9 2-(4-methoxy-3-nitrobenzylsulfonyl)acetyl chloride 
• 1310064-84-6 C₁₉H₂₁NO₈S 
• 852285-78-0 2-(4-methoxy-3-nitrobenzylsulfinyl)acetic acid 
• 852283-23-9 (E)-1,3,5-trimethoxy-2-(2-(4-methoxy-3-nitrobenzylsulfinyl)vinyl)benzene 
• 1310064-99-3 C₂₃H₂₉NO₈S 
• 1310064-85-7 (E)-2',6'-dimethoxystyryl-4-methoxy-3-nitrobenzylsulfone 
• 1310064-86-8 C₁₈H₁₉NO₇S 
• 592542-50-2 (E)-2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)aniline 
• 1310064-87-9 C₁₉H₂₃NO₆S 
• 1310064-88-0 (E)-2',5'-dimethoxystyryl-4-methoxy-3-aminobenzylsulfone 
• 1310064-89-1 C₁₈H₂₁NO₅S 
• 592542-78-4 (E)-2,4,6-trimethoxystyryl-3-(acetamido)-4-methoxybenzylsulfone 

Relevant articles and documents

Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance

Inhibiting/disturbing the RAS/RAF pathway may benefit the treatment of cancer and overcome the resistance. Utilizing such a pathway as the target, nine styrylbenzylsulfone derivatives generated from the platinum-based modification of the side chain of Rig

Method for preparing new anti-tumor drug Rigosertib

The invention relates to a method for preparing new anti-tumor drug Rigosertib. By adopting the method provided by the invention, the post-treatment of each step is simple to operate, the target product can be obtained, and the operability of industrial p

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): Synthesis, structure-activity relationship, and biological activity

Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer. Accordingly, there is an increasing awareness of this novel nonenzymatic target for cancer therapeutics. We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells. The development of derivatized styrylbenzylsulfones followed logically from a tumor cell cytotoxicity screen performed in our laboratory that did not have an a priori target profile. Modifications of some of the precursor molecules led to lead optimization with regard to tumor cell cytotoxicity. In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2′,4′,6′- trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) associated with aberrant expression of cyclin D proteins.